Drug
Pamiparib clinical trials
Also written BGB-290.
- studies test it
- 28
- open now
- 5
- in phase 3
- 2
- first study started
- 2014
Keep track of what changes. Save the pamiparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- BGB-290
- 16
Combined with it in one product
Studies by the year they started
28 studies that test it; most in 2022 (10)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 5 |
| 2021 | 2 |
| 2022 | 10 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 18
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 18
BeiGene (9) · Sun Yat-sen University (3) · University of California, San Francisco (1) · Zhejiang Cancer Hospital (1) · BeOne Medicines (1) · Nader Sanai (1) · M.D. Anderson Cancer Center (1) · Tongji Hospital (1)
Often tested with
Tested in the same studies.
Tislelizumab (7) · Temozolomide (4) · Surufatinib (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Cisplatin (2) · Sitravatinib (1) · Hpk1 Inhibitor BGB-15025 (1)
Studies
Open first, then newest update. How each study uses pamiparib is read from its arms, and is right about nine times in ten.
Testing it · 28
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingPhase 2Bai-Rong XiaNCT05652283Written as Pamiparib
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerRecruitingPhase 1University of ChicagoNCT05526924Written as Pamiparib
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Pamiparib
- Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06387056Written as Pamiparib
- A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair DefectsRecruitingPhase 2Peter MacCallum Cancer Centre, AustraliaNCT04985721Written as Pamiparib
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedPhase 3BeOne MedicinesNCT04164199Written as Pamiparib
- Study of Pamiparib in Newly Diagnosed and rGBMCompletedEarly Phase 1Nader SanaiNCT04614909Written as Pamiparib
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid TumorsCompletedPhase 1M.D. Anderson Cancer CenterNCT05038839Written as Pamiparib
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerActive, not recruitingPhase 3BeiGeneNCT03519230Written as Pamiparib capsule
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV GliomasActive, not recruitingPhase 1University of California, San FranciscoNCT03749187Written as PARP Inhibitor BGB-290
- Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerCompletedPhase 1/2Sun Yat-sen UniversityNCT05494580Written as Pamiparib
- Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedPhase 2Tongji HospitalNCT05044871Written as Pamiparib
- Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid TumorsCompletedPhase 1/2BeiGeneNCT03333915Written as Pamiparib
- Phase 1a/1b BGB-290 for Advanced Solid Tumors.CompletedPhase 1BeiGeneNCT02361723Written as BGB-290
- Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1BeiGeneNCT03150810Written as Pamiparib
- Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in ChinaCompletedPhase 2BeiGeneNCT03575065Written as BGB-290
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedPhase 2BeiGeneNCT03427814Written as Pamiparib
- Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With CancerCompletedPhase 1BeiGeneNCT03994211Written as pamiparib 60 mg
- A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor ExposureActive, not recruitingPhase 2Zhejiang Cancer HospitalNCT05489926Written as Pamiparib
- Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell CancerWithdrawnPhase 2Jonsson Comprehensive Cancer CenterNCT04603365Written as Pamiparib
See all 28 studies that test pamiparib →
Given in every arm · 3 — pamiparib is usual care beside what is tested
- Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung CancerRecruitingPhase 1Affiliated Hospital of Jiangnan UniversityNCT05573373Written as Parimparib
- A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent GlioblastomaCompletedPhase 1/2BeiGene USA, Inc.NCT03150862Written as Pamiparib
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 MutationsCompletedPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03914742Written as PARP Inhibitor BGB-290
Codes
What other systems call pamiparib · ClinicalTrials.gg INT001345
- MeSH (NLM) C000707927pamiparibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8375F9S90CPAMIPARIBConfirmed FDA, NLM, Wikidata
- Wikidata Q125351134pamiparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C120553PamiparibOne source FDA
- DrugBank DB14769One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707927 | pamiparib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8375F9S90C | PAMIPARIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q125351134 | pamiparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C120553 | Pamiparib | One source FDA |
| DrugBank | DB14769 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.